- Report
- April 2025
- 363 Pages
Global
From €5324EUR$5,850USD£4,564GBP
- Drug Pipelines
- March 2025
- 280 Pages
Global
From €2730EUR$3,000USD£2,341GBP
- Report
- August 2024
- 150 Pages
Global
From €3521EUR$3,869USD£3,019GBP
- Clinical Trials
- April 2024
- 100 Pages
Global
From €2730EUR$3,000USD£2,341GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €2503EUR$2,750USD£2,146GBP
- Report
- February 2022
- 308 Pages
Global
From €8646EUR$9,500USD£7,412GBP
- Report
- June 2022
- 117 Pages
Global
From €4323EUR$4,750USD£3,706GBP
- Report
- January 2022
- 121 Pages
Global
From €4323EUR$4,750USD£3,706GBP
- Report
- August 2023
- 86 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- April 2025
- 65 Pages
Global
From €2412EUR$2,650USD£2,068GBP
- Report
- August 2024
- 199 Pages
China
From €3640EUR$4,000USD£3,121GBP
- Report
- August 2024
- 98 Pages
China
From €1638EUR$1,800USD£1,404GBP

Irinotecan is a semi-synthetic derivative of the natural product camptothecin, a quinoline alkaloid found in the bark of the Chinese tree Camptotheca acuminata. It is used as an antineoplastic agent in the treatment of a variety of cancers, including colorectal, lung, ovarian, and pancreatic cancer. Irinotecan is a topoisomerase I inhibitor, meaning it interferes with the enzyme topoisomerase I, which is involved in DNA replication.
Irinotecan is available in both generic and branded forms, with the branded form being marketed under the trade name Camptosar. It is available in both intravenous and oral formulations, and is typically administered in combination with other chemotherapy agents.
The Irinotecan market is highly competitive, with a number of major players operating in the space. These include Pfizer, Teva Pharmaceuticals, Mylan, Sandoz, and Sun Pharmaceuticals. Additionally, there are a number of smaller players operating in the market, such as Dr. Reddy's Laboratories, Intas Pharmaceuticals, and Natco Pharma. Show Less Read more